# Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation

> **NCT05031026** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Assiut University** · enrollment: 60 (estimated)

## Conditions studied

- Liver Transplant; Complications

## Interventions

- **DRUG:** Dexmedetomidine
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT05031026
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-15
- **Primary completion:** 2025-12-15
- **Final completion:** 2026-02-15
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05031026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05031026, "Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05031026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*